2269:HKG
WuXi Biologics (Cayman) Inc
HK$48,20
arrow_downward
-0,90%(-0,44) 1G
16 Eki, 16:08:14 GMT+8 · HKD
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_auto2269 ile ilgili en önemli analizler oluşturuluyor...
Açık
HK$49,98
Yüksek
HK$50,85
Düşük
HK$45,82
Piy. değ.
198,43 Mr
Ort. hacim
30,42 Mn
İşlem Hacmi
55,18 Mn
F/K oranı
34,48
52 haftalık en yüksek
HK$58,00
52 haftalık en düşük
HK$28,48
HBK
HK$1,40
Tedavüldeki hisse senedi sayısı
1,23 Mr
Çalışan sayısı
15 B
Açık
HK$49,98
Yüksek
HK$50,85
Düşük
HK$45,82
Piy. değ.
198,43 Mr
Ort. hacim
30,42 Mn
İşlem Hacmi
55,18 Mn
F/K oranı
34,48
52 haftalık en yüksek
HK$58,00
52 haftalık en düşük
HK$28,48
HBK
HK$1,40
Tedavüldeki hisse senedi sayısı
1,23 Mr
Çalışan sayısı
15 B
Haberler
Web kaynaklarından ve haber iş ortaklarından
Business Wire
·
14 dakika önce
Power Integrations Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
44 dakika önce
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
·
29 dakika önce
GreenPower Announces Receipt of Letter from NASDAQ
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
WuXi Biologics (Cayman) Inc hakkında
CEOZhisheng Chen
Çalışan Sayısı14,7 B
Kuruluş Tarihi2010
Genel Merkez-
Sektör-
Web Sitesiwuxibiologics.com